Speciality Medicines Share Price & Earnings Call Analysis
- Market cap
- ₹123 Cr
- P/E
- 9.45
- ROE
- 25.57%
- PEG
- 0.10
- Price to sales
- 1.63
- Debt to equity
- 0.09
- EBITDA margin
- 18.17%
- Net profit margin
- 17.29%
- Promoter holding
- 43.43%
- Sales (last year)
- ₹75 Cr
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹480 Cr | 19.1 | |
| 2 | 40%+ | Up 0–2% | ₹212 Cr | 16.1 | |
| 3 | 40%+ | Flat | ₹17,925 Cr | — | |
| 4 | 40%+ | Flat | ₹5,223 Cr | 39.1 | |
| 5 | 40%+ | Flat | ₹4,268 Cr | — | |
| 6 | 40%+ | Flat | ₹40 Cr | — |
Sign up free to see every company in the sector ranking and track Speciality Medicines.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Speciality Medicines
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Speciality Medicines
Quarterly Results
Quarter-by-quarter operating performance
Financials of Speciality Medicines
Profit & Loss
Annual income statement trend
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales + | 40 | 23 | 28 | 58 | 75 |
| Expenses + | 38 | 20 | 22 | 49 | 62 |
| Operating Profit | 2 | 4 | 5 | 9 | 14 |
| OPM % | 6% | 15% | 19% | 16% | 18% |
| Other Income + | 0 | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 2 | 3 | 5 | 9 | 13 |
| Tax % | 31% | 43% | 36% | 1% | -0% |
| Net Profit + | 1 | 2 | 3 | 9 | 13 |
| EPS in Rs | 70.48 | 4.42 | 5.73 | 13.38 | 14.83 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Financials of Speciality Medicines
Balance Sheet
Capital structure and asset base
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 0.21 | 4 | 5 | 6 | 9 |
| Reserves | 2 | 2 | 10 | 24 | 62 |
| Borrowings + | 1 | 4 | 3 | 5 | 7 |
| Other Liabilities + | 3 | 4 | 5 | 5 | 17 |
| Total Liabilities | 6 | 13 | 23 | 40 | 95 |
| Fixed Assets + | 2 | 2 | 1 | 2 | 2 |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 4 | 11 | 21 | 38 | 93 |
| Total Assets | 6 | 13 | 23 | 40 | 95 |
Financials of Speciality Medicines
Cash Flows
Operating, investing and financing cash movement
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from Operating Activity + | 1 | -4 | -5 | -6 | |
| Cash from Investing Activity + | -2 | 0 | -0 | -2 | |
| Cash from Financing Activity + | 2 | 4 | 5 | 8 | |
| Net Cash Flow | 0 | 0 | -0 | 1 | |
| Free Cash Flow | -1 | -4 | -5 | -6 | |
| CFO/OP | 36% | -101% | -66% | -63% |
Financials of Speciality Medicines
Ratios
Working capital efficiency and return ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 23 | 87 | 142 | 60 | 128 |
| Inventory Days | 5 | 103 | 161 | 150 | 191 |
| Days Payable | 12 | 40 | 48 | 8 | 80 |
| Cash Conversion Cycle | 16 | 149 | 255 | 202 | 239 |
| Working Capital Days | -3 | 76 | 185 | 180 | 221 |
| ROCE % | 52% | 38% | 34% | 25% |
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Aarti Drugs (Q2 FY27)
826.2 Crore, up 27% YoY from Rs. Key investor presentation takeaways from Aarti Drugs Ltd's Q2 FY27 investor presentation — and how it ranks against sector peer
- Anthem Bioscienc (Q2 FY27)
Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc
- Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
- Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest